Arrowhead Pharmaceuticals celebrates FDA approval for new rare disease therapy

Arrowhead Pharmaceuticals celebrates FDA approval for new rare disease therapy
@ArrowheadPharma: FDA approves new FCS therapy

Arrowhead Pharmaceuticals has achieved a significant milestone with the FDA approval of its new therapy designed to lower triglycerides for adults suffering from Familial Chylomicronemia Syndrome (FCS).

Dr. Jennifer Hellawell characterized this approval with a single word: 'Exhilaration.' For patients dealing with this rare disease, the newly approved treatment brings hope and the potential for better disease management.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.